A randomised controlled trial of intramuscular vs, intravenous antivenom for latrodectism - the RAVE study

G.K. Isbister, Simon Brown, M. Miller, A. Tankel, Elena Macdonald, B. Stokes, R. Ellis, Yusuf Nagree, Garry Wilkes, R. James, A. Short, A. Holdgate

    Research output: Contribution to journalArticlepeer-review

    25 Citations (Scopus)

    Abstract

    Background: Widow spider-bite causes latrodectism and is associated with significant morbidity worldwide. Antivenom is given by both the intravenous (IV) and intramuscular (IM) routes and it is unclear which is more effective.Aim: To compare the effectiveness of IV vs. IM redback spider antivenom.Design: Randomized controlled trial.Methods: Patients with latrodectism were given either IV or IM antivenom according to a randomized double-dummy, double-blind protocol. The first antivenom treatment was followed by another identical treatment after two hours if required. The primary outcome was a clinically significant reduction in pain two hours after the last treatment. A fully Bayesian analysis was used to estimate the probability of the desired treatment effect, predetermined as an absolute difference of 20.Results: We randomly allocated 126 patients to receive antivenom IV (64) and IM (62). After antivenom treatment pain improved in 40/64(62) in the IV group vs. 33/62(53) in the IM group (+9; 95 Credible Interval [CrI]: -8% to +26). The probability of a difference greater than zero (IV superior) was 85% but the probability of a difference <20 was only 10%. In 55 patients with systemic effects, these improved in 58% after IV antivenom vs. 65 after IM antivenom (-8%; 95% Crl: 32% to +17%). Twenty-four hours after antivenom pain had improved in 84 in the IV group vs. 71% in the IM group (+13%; 95% Crl: -2% to 27%). A meta-analysis including data from a previous trial found no difference in the primary outcome between IV and IM administration.Discussion: The difference between IV and IM routes of administration of widow spider antivenom is, at best, small and does not justify routinely choosing one route over the other. Furthermore, antivenom may provide no benefit over placebo.
    Original languageEnglish
    Pages (from-to)557-565
    JournalQJM: an international journal of medicine
    Volume101
    Issue number7
    DOIs
    Publication statusPublished - 2008

    Fingerprint

    Dive into the research topics of 'A randomised controlled trial of intramuscular vs, intravenous antivenom for latrodectism - the RAVE study'. Together they form a unique fingerprint.

    Cite this